• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nuvation Bio Inc.

    11/3/25 4:53:13 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVB alert in real time by email
    S-8 1 d30841ds8.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on November 3, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    NUVATION BIO INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   85-0862255

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    1500 Broadway, Suite 1401

    New York, New York 10036

    (Address of principal executive offices, including zip code)

    Nuvation Bio Inc. 2021 Equity Incentive Plan

    Nuvation Bio Inc. 2021 Employee Stock Purchase Plan

    (Full titles of the plans)

    Philippe Sauvage

    Chief Financial Officer

    Nuvation Bio Inc.

    1500 Broadway, Suite 1401

    New York, New York 10036

    (332) 208-6102

    (Name, address and telephone number, including area code, of agent for service)

    Copies to:

     

    Stephen Dang

    Senior Vice President, General Counsel

    Nuvation Bio Inc.

    1500 Broadway, Suite 1401

    New York, New York 10036

    (332) 208-6102

     

    Kenneth L. Guernsey

    John T. McKenna

    Cooley LLP

    3 Embarcadero Center, 20th Floor

    San Francisco, California 94111

    (415) 693-2000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 16,227,731 shares of the Class A Common Stock of Nuvation Bio Inc. (the “Registrant”) to be issued pursuant to the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”) and 4,056,932 shares of the Class A Common Stock of the Registrant to be issued pursuant to the Registrant’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”).

    PART II

     

    ITEM 3.

    INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Securities and Exchange Commission are incorporated by reference into this Registration Statement:

    (a) The contents of the earlier registration statements on Form S-8 and exhibits thereto relating to the 2021 Plan and the 2021 ESPP, filed with the Securities and Exchange Commission on June  8, 2021 (File No. 333-526910), August  26, 2022 (File No. 333-267110), March  16, 2023 (File No. 333-270614), and March  4, 2024 (File No. 333-277646).

    (b)  The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, which includes audited financial statements for the Registrant’s latest fiscal year, filed with the Securities and Exchange Commission on March 6, 2025.

    (c) The Registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the SEC on May 7, 2025, August  7, 2025 and November 3, 2025, respectively).

    (d) The Registrant’s Current Reports on Form 8-K filed with the Commission on February  12, 2025, March  4, 2025, March  5, 2025, March  25, 2025, May  23, 2025 and June 11, 2025.

    (e) The description of our Class  A Common Stock which is contained in a Registration Statement on Form 8-A filed on June 26, 2020 (File No. 001-39351) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    ITEM 8.

    EXHIBITS

     

    Exhibit

    Number

       Description
      5.1    Opinion of Cooley LLP.
     23.1    Consent of KPMG LLP, Independent Registered Public Accounting Firm.
     23.2    Consent of Cooley LLP (included in Exhibit 5.1).
     24.1    Power of Attorney (included on the signature page).
    107    Filing Fee Table.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on November 3, 2025.

     

    NUVATION BIO INC.
    By:  

    /s/ David Hung, M.D.

      David Hung, M.D.
      Founder, President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Hung, M.D. and Philippe Sauvage, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ David Hung, M.D.

    David Hung, M.D.

       Chairman of the Board, President and Chief Executive Officer
    (Principal Executive Officer)
      November 3, 2025

    /s/ Philippe Sauvage

    Philippe Sauvage

      

    Chief Financial Officer

    (Principal Financial Officer)

      November 3, 2025

    /s/ Moses Makunje

    Moses Makunje

      

    Vice President, Finance

    (Principal Accounting Officer)

      November 3, 2025

    /s/ Robert B. Bazemore Jr.

    Robert B. Bazemore Jr.

       Lead Independent Director   November 3, 2025

    /s/ Kim Blickenstaff

    Kim Blickenstaff

       Director   November 3, 2025

    /s/ Min Cui, Ph.D.

    Min Cui, Ph.D.

       Director   November 3, 2025

    /s/ Kathryn E. Falberg

    Kathryn E. Falberg

       Director   November 3, 2025

    /s/ Robert Mashal, M.D.

    Robert Mashal, M.D.

       Director   November 3, 2025

    /s/ W. Anthony Vernon

    W. Anthony Vernon

       Director   November 3, 2025
    Get the next $NUVB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVB

    DatePrice TargetRatingAnalyst
    9/30/2025$10.00Buy
    Jefferies
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    3/27/2024$1.40 → $10.00Hold → Buy
    Jefferies
    3/26/2024$5.00Neutral → Buy
    BTIG Research
    1/6/2023$5.00 → $2.00Buy → Hold
    Jefferies
    8/2/2022$8.00 → $2.50Outperform → Market Perform
    BMO Capital Markets
    8/2/2022Buy → Neutral
    BTIG Research
    5/4/2022$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $NUVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:15 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:21 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:19 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

    Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's unprecedented durability in TKI-naïve, advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) increased to 50 months as of August 2025 Enrolled first patient in global, randomized study of safusidenib with registrational intent for maintenance treatment of high-grade IDH1-mutant glioma Enrolled first patient in TRUST-IV phase 3 study of IBTROZI for the adjuvant treatment of ROS1+ early-stage NSCLC Strong balance sheet with cash, cash equivalents, and marketable securities of $549.0 million as of Septembe

    11/3/25 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio to Participate in Upcoming Investor Conferences

    Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor conferences, including fireside chats at two conferences: Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, at 10:00 a.m. ET/3:00 p.m. GMT in London, U.K. 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL The management team will participate in one-on-one meetings at the 2025

    10/30/25 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

    No targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase 3 trial to support potential registration Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 (NCT05303519), a global, randomized study evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-grade IDH1-mutant astrocytoma following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Safusidenib is a nove

    10/23/25 7:30:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Nuvation Bio with a new price target

    Jefferies initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $10.00

    9/30/25 8:57:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Nuvation Bio with a new price target

    Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00

    4/23/25 8:17:12 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio upgraded by Jefferies with a new price target

    Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously

    3/27/24 8:16:27 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Hattersley Gary exercised 100,000 shares at a strike of $1.74 and sold $502,460 worth of shares (100,000 units at $5.02) (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    10/29/25 4:24:30 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mashal Robert

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    8/13/25 4:30:14 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:15 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

    Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

    10/7/24 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

    Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

    5/14/24 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

    Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

    3/28/24 8:00:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    SEC Filings

    View All

    SEC Form S-8 filed by Nuvation Bio Inc.

    S-8 - Nuvation Bio Inc. (0001811063) (Filer)

    11/3/25 4:53:13 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nuvation Bio Inc.

    10-Q - Nuvation Bio Inc. (0001811063) (Filer)

    11/3/25 4:22:53 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Nuvation Bio Inc.

    8-K - Nuvation Bio Inc. (0001811063) (Filer)

    11/3/25 4:15:31 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Financials

    Live finance-specific insights

    View All

    Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

    Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's unprecedented durability in TKI-naïve, advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) increased to 50 months as of August 2025 Enrolled first patient in global, randomized study of safusidenib with registrational intent for maintenance treatment of high-grade IDH1-mutant glioma Enrolled first patient in TRUST-IV phase 3 study of IBTROZI for the adjuvant treatment of ROS1+ early-stage NSCLC Strong balance sheet with cash, cash equivalents, and marketable securities of $549.0 million as of Septembe

    11/3/25 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

    Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 405112. An archived recording will be available on Nuvation Bio's website for 90 days following the event. A

    10/20/25 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

    Received U.S. Food and Drug Administration (FDA) approval for IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) on June 11, 2025 Successfully started 70 patients on IBTROZI as of July 31, 2025, approximately seven weeks after U.S. FDA approval National Comprehensive Cancer Network® added taletrectinib (IBTROZI) as a Preferred Option to Clinical Practice Guidelines in Oncology for advanced ROS1+ NSCLC on June 20, 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $607.7 million as of June 30, 2025 Company to host a conference call today at 8:00 a.m. ET Nuvation Bio Inc. (

    8/7/25 7:30:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

    SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

    11/12/24 10:32:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

    SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

    10/18/24 4:15:55 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Nuvation Bio Inc.

    SC 13D - Nuvation Bio Inc. (0001811063) (Subject)

    9/10/24 4:51:38 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care